Detection and Analysis of MBC With Heterogeneous ER Expression

Completed

• Conditions: Breast Cancer

• Registration Number: NCT05392985
• Lead Sponsor: Fudan University

Brief Summary

To investigate the treatment pattern and efficacy of MBC patients with ER heterogeneity using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).

Detailed Description

Not available

Study Timeline

• Study Start: 2022-01-15
• Study First Submitted: 2022-05-23
• Study First Submitted QC: 2022-05-23
• Study First Posted: 2022-05-26
• Primary Completion: 2022-12-15
• Study Completion: 2022-12-15
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-23
• Last Update Posted: 2024-02-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 51

Inclusion Criteria

• Patients received 18F-FES PET/CT in Fudan University Shanghai Cancer Center from 2017-2021.
• Patients had both FES positive (FES+) and negative (FES-) lesions in FES exam.
• Patients received further treatment.

Read More

Exclusion Criteria

• Incomplete medical records.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PFS	6 weeks	Progression free survival

Secondary Outcome Measures

Name	Time	Method
Adverse events	6 weeks	Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0

Trial Locations

Locations (1)

Fudan University Shanghai Cancer Center; 🇨🇳 Shanghai, Shanghai, China